Cargando…

Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment

Mesothelin (MSLN), a glycoprotein normally expressed by mesothelial cells, is overexpressed in ovarian cancer (OvCa) suggesting a role in tumor progression, although the biological function is not fully understood. OvCa has a high mortality rate due to diagnosis at advanced stage disease with intrap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hilliard, Tyvette S., Kowalski, Brooke, Iwamoto, Kyle, Agadi, Elizabeth A., Liu, Yueying, Yang, Jing, Asem, Marwa, Klymenko, Yuliya, Johnson, Jeff, Shi, Zonggao, Marfowaa, Gifty, Yemc, Madeleine G., Petrasko, Phillip, Stack, M. Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623331/ https://www.ncbi.nlm.nih.gov/pubmed/34830322 http://dx.doi.org/10.3390/ijms222212443

Ejemplares similares

Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue()
por: Loughran, Elizabeth A., et al.
Publicado: (2018)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer
por: Asem, Marwa, et al.
Publicado: (2020)

Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation
por: Coelho, Ricardo, et al.
Publicado: (2020)

Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy
por: Liu, Yueying, et al.
Publicado: (2023)

Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer
por: Klymenko, Yuliya, et al.
Publicado: (2017)

Lysophosphatidic acid modulates ovarian cancer multicellular aggregate assembly and metastatic dissemination
por: Klymenko, Yuliya, et al.
Publicado: (2020)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Advanced Glycation End Products as a Potential Target for Restructuring the Ovarian Cancer Microenvironment: A Pilot Study
por: Harper, Elizabeth I., et al.
Publicado: (2023)

Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema With Resultant Airway Obstruction Following Endotracheal Intubation
por: Vazirnia, Parsia, et al.
Publicado: (2023)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Gonadotropins Activate Oncogenic Pathways to Enhance Proliferation in Normal Mouse Ovarian Surface Epithelium
por: Hilliard, Tyvette S., et al.
Publicado: (2013)

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
por: Mizukami, Tatsuzo, et al.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled
por: Klymenko, Yuliya, et al.
Publicado: (2018)

Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates
por: Klymenko, Yuliya, et al.
Publicado: (2018)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Fluorescence In Situ Hybridization for MicroRNA Detection in Archived Oral Cancer Tissues
por: Shi, Zonggao, et al.
Publicado: (2012)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Cadherin Composition and Multicellular Aggregate Invasion In Organotypic Models of Epithelial Ovarian Cancer Intraperitoneal Metastasis
por: Klymenko, Yuliya, et al.
Publicado: (2017)

Heterogeneous Cadherin Expression and Multicellular Aggregate Dynamics in Ovarian Cancer Dissemination
por: Klymenko, Yuliya, et al.
Publicado: (2017)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Chemical Analysis of Morphological Changes in Lysophosphatidic Acid-Treated Ovarian Cancer Cells
por: Bailey, Karen A., et al.
Publicado: (2017)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2s2vo2v4mtqvjaqiqk3dier3ma